AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$MCK

McKesson’s (NYSE:MCK) Q3 CY2026 adjusted EPS top estimates

McKesson reported Q3 revenue of $111 billion, beating estimates by 0.8% and showing 7.6% YoY growth. Adjusted EPS was $11.68, an 8.6% beat. Management raised full-year adjusted EPS guidance to $46 at the midpoint, up 3.1%. Operating and free cash flow margins remained steady.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
McKesson’s (NYSE:MCK) Q3 CY2026 adjusted EPS top estimates — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short-term buying interest.

02

Market read

Large-cap healthcare distributor delivering better-than-expected results, potential catalyst for sector.

03

What to watch

Free cash flow margin remains low, indicating cash generation constraints.

Relevance 9/10Novelty 9/10Timing: after-hours release

Background

McKesson reported Q3 2026 results, surpassing consensus estimates and raising full-year EPS guidance.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

Q3 2026 results beat revenue and EPS estimates and full-year EPS guidance was raised to $46.

Expected impact

likely upside as market prices in the earnings beat and guidance raise

Evidence & confidence

Revenue $111B beat consensus, EPS $11.68 beat $10.75, and full-year EPS guidance increased 3.1%.

Market effects

Sector

Healthcare distribution sector may see broader optimism from McKesson's beat.

Regional

U.S. market may see a modest lift in related pharma distributors.

Global

Limited to U.S. healthcare supply chain participants.

Counterpoint

What could challenge this read

Investors may question sustainability of margin expansion given flat operating margin.

Key entities

  • Company
    McKesson Corporation

    U.S. pharmaceutical distributor reporting Q3 2026 earnings.

Read at source← All news

StoryMcKesson posts strong Q2 FY2027 results, raises FY2027 EPS guidance and completes Precision Medicine Group acquisition

Also covered by

6 outlets

Related articles

$MCKHighAI 8/10

McKesson (MCK) Q2 2027 Earnings Call Transcript

McKesson (MCK) reported Q2 2027 earnings, highlighting investments in employee programs and strategic acquisitions. The company acquired Precision Medicine Group to advance its oncology and biopharma services, and plans to invest in Option Care Health. McKesson also extended its distribution agreement with CVS Health. The company reported strong market trends and growth across its platforms, with a focus on technology and automation to enhance services.

finance.yahoo.com
$MCKHighAI 9/10

Key facts: FY27 Outlook Raised; Deals Expanded; PMG Buy, Segment Split

McKesson (MCK) reported Q2 revenue of $110.96B (+8% YoY) and adjusted EPS of $11.68, beating estimates. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company extended a drug distribution deal with CVS Health and plans to buy 49% of Option Care Health for $1.4B. McKesson also completed its acquisition of Precision Medicine Group and announced plans to separate its medical-surgical solutions segment.

tradingview.com
$MCKHighAI 9/10

McKesson Corp (MCK) (Q2 2027) Earnings Call Highlights: Raised Guidance, GLP-1 Momentum

McKesson Corp (MCK) raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40, citing 8% revenue growth to $111 billion in Q2. The company acquired Precision Medicine Group for $2.25 billion, extending oncology capabilities. Challenges include lower branded pharmaceutical pricing and medical-surgical segment profit decline. Management discussed strategic investments and long-term growth targets.

finance.yahoo.com
$MCKMedAI 8/10

McKesson Q2 Revenue Rises to $110.96B, EPS $10.44; $221M Restructuring Charge

McKesson reported fiscal Q2 2027 revenue of $110.96B, up from $103.15B a year earlier, with net income of $1.22B and EPS of $10.44. The company recorded $221M in restructuring charges for the six-month period. Gross profit rose to $3.96B, while operating income increased to $1.60B. Share buybacks reduced the weighted-average diluted shares, supporting per-share results. The company faces risks related to opiate litigation and rising interest expenses.

minichart.com.sg
$MCKHighAI 8/10

[McKesson Q2 2027 Earnings Call] McKesson Raises FY2027 EPS Guidance to $45.60-$46.40, Beats on 8% Revenue Growth and 26% GLP-1 Surge

McKesson (MCK) raised its FY2027 EPS guidance to $45.60-$46.40, up from $44.20-$45.00, citing 8% revenue growth and a 26% surge in GLP-1 medication sales. Q2 revenue was $111.0B, up 8%, with adjusted EPS at $11.68, up 18%. The company completed a $2.25B acquisition and plans a $1.4B investment. Management expects 6-10% revenue growth and 12-16% operating profit growth for FY2027.

finance.biggo.com